Status:
COMPLETED
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Overweight
Obesity
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years. This is to compare the effect on body weight in people taking semaglut...
Eligibility Criteria
Inclusion
- Male or female, age 18 years or older at the time of signing informed consent
- Body mass index (BMI) equal to or above 30.0 kg/m\^2 or equal to or above 27.0 kg/m\^2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease
- History of at least one self-reported unsuccessful dietary effort to lose body weight
Exclusion
- HbA1c equal to or above 48 mmol/mol (6.5%) as measured by the central laboratory at screening
- History of type 1 or type 2 diabetes mellitus
- A self-reported change in body weight of more than 5 kg (11 lbs) within 90 days before screening irrespective of medical records
Key Trial Info
Start Date :
September 11 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 11 2021
Estimated Enrollment :
338 Patients enrolled
Trial Details
Trial ID
NCT04074161
Start Date
September 11 2019
End Date
May 11 2021
Last Update
May 19 2023
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Birmingham, Alabama, United States, 35294
2
Novo Nordisk Investigational Site
Fullerton, California, United States, 92835
3
Novo Nordisk Investigational Site
Huntington Beach, California, United States, 92648
4
Novo Nordisk Investigational Site
Jacksonville, Florida, United States, 32205